Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Sclerosis symbols : Nvsef save search
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -3.05%
H: 1.75%
C: 0.5%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: -0.07%
H: 0.46%
C: -0.31%
tyruko europe biosimilar approval sclerosis
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Published: 2023-08-25 (Crawled : 06:00) - globenewswire.com
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
tyruko fda biosimilar approval sclerosis
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Published: 2023-07-24 (Crawled : 06:00) - globenewswire.com
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: -0.05%
H: 0.24%
C: -0.83%
biosimilar chmp positive sclerosis
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Published: 2023-04-20 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.34%
H: 0.28%
C: 0.25%
kesimpta sclerosis novartis living
New Drug, TASCENSO ODT® (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
Published: 2023-02-13 (Crawled : 15:20) - biospace.com/
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.39%
H: 0.81%
C: 0.77%
odt sclerosis
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)
Published: 2023-01-17 (Crawled : 19:00) - biospace.com/
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 2.34%
H: 0.04%
C: -0.87%
odt pharmaceuticals program approval sclerosis
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Published: 2022-07-25 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.12%
H: 0.06%
C: 0.06%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: 0.19%
fda biosimilar ema sclerosis multiple sclerosis
Neurodegenerative Diseases Therapeutics Market Size to grow by USD 19.74 billion from 2021 to 2026| Multiple Sclerosis Segment to be Significant for Revenue Generation| Technavio
Published: 2022-04-29 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -0.99%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.19%
H: 0.59%
C: -1.36%
ABBV | News | $165.09 0.26% 760K
|
Health Technology
|
| O: -4.81%
H: 0.2%
C: -1.79%
SNY | News | $46.135 1.64% 270K
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
BIIB | $190.99 0.25% 180K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
ACAD | $17.21 0.82% 88K
|
Health Technology
|
| O: -0.63%
H: 1.85%
C: -2.33%
therapeutics neurodegenerative sclerosis market
Ontario and Quebec become the first provinces to list Kesimpta (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
treatment sclerosis multiple sclerosis
Multiple Sclerosis Market in the US to Grow by USD 3.95 billion | Strong Pipeline to Drive Market Growth | Technavio
Published: 2022-03-07 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 7.22%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
VTRS | $11.26 1.26% 500K
|
Health Technology
|
| O: -0.7%
H: 1.2%
C: -1.2%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
SNY | News | $46.135 1.64% 270K
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
BIIB | $190.99 0.25% 180K
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
multiple sclerosis sclerosis growth
Multiple Sclerosis Drugs Market size worth $ 42.46 Billion, Globally, by 2028 at 6.3% CAGR: Verified Market Research®
Published: 2022-02-09 (Crawled : 14:30) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 2.73%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
JNJ | News | $146.315 0.4% 1.3M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
SNY | News | $46.135 1.64% 270K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
research multiple sclerosis drug sclerosis
Novartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem Neurosciences
Published: 2021-10-05 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.2%
H: 0.0%
C: 0.0%
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: -0.56%
H: 0.33%
C: -0.2%
multiple sclerosis partnership sclerosis
Gainers vs Losers
| 84% | 16% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
CHRO | $1.73 41.22% 46K
|
n/a
RWOD | $10.61 32.68% 5.1M
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
PRTG | $0.285 18.75% 140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.